{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:41:44Z","timestamp":1760384504846},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.bcp.2005.10.038","type":"journal-article","created":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T12:41:32Z","timestamp":1133268092000},"page":"1057-1065","source":"Crossref","is-referenced-by-count":14,"title":["The role of pharmacodynamic research in the assessment and development of new antibacterial drugs"],"prefix":"10.1016","volume":"71","author":[{"given":"Philip D.","family":"Lister","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2005.10.038_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/AAC.39.5.1054","article-title":"Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models","volume":"39","author":"Keil","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1128\/AAC.29.5.765","article-title":"Artifacts in dlution pharmacokinetic models caused by adherent bacteria","volume":"29","author":"Haag","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/infdis\/144.6.583","article-title":"An artificial capillary in vitro kinetic model of antibacterial activity","volume":"144","author":"Zinner","year":"1981","journal-title":"J Infect Dis"},{"issue":"Suppl A","key":"10.1016\/j.bcp.2005.10.038_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/jac\/15.suppl_A.131","article-title":"Two compartment kinetic model with multiple artificial capillary units","volume":"15","author":"Blaser","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib5","first-page":"122","article-title":"On the duration of penicillin action in relation to its concentration in the serum","volume":"40","author":"Eagle","year":"1953","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.bcp.2005.10.038_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0002-9343(50)90425-6","article-title":"Effect of schedule of administration on the therapeutic efficacy of penicillin","volume":"9","author":"Eagle","year":"1950","journal-title":"Am J Med"},{"key":"10.1016\/j.bcp.2005.10.038_bib7","series-title":"Antimicrobial pharmacodynamics in theory and clinical practice","first-page":"67","article-title":"Animal models of infection for the study of antibiotic pharmacodynamics","author":"Dudley","year":"2002"},{"key":"10.1016\/j.bcp.2005.10.038_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/jps.2600741017","article-title":"Pharmacokinetic scale-up: Accurate prediction of human pharmacokinetic profiles from animal data","volume":"74","author":"Mordenti","year":"1985","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bcp.2005.10.038_bib9","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1128\/AAC.42.9.2375","article-title":"In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determination","volume":"42","author":"Andes","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1988.tb03281.x","article-title":"The effect of probenicid on the renal tubular excretion of benzylpenicillin","volume":"25","author":"Overbosch","year":"1988","journal-title":"Br J Clin Pharm"},{"key":"10.1016\/j.bcp.2005.10.038_bib11","first-page":"189","article-title":"Dose ranging of the pharmacodynamics of cefoperazone plus sulbactam in an in vitro model of infection: comparison using a new parameter \u2013 area under the survival fraction versus time curve","volume":"9","author":"Dudley","year":"1989","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bcp.2005.10.038_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1128\/AAC.33.9.1500","article-title":"Antipseudomonal activity of simulated infusion of gentamycin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve","volume":"33","author":"Tisdale","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib13","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1128\/AAC.36.12.2741","article-title":"Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model","volume":"36","author":"McGrath","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib14","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/AAC.41.9.1926","article-title":"Rationale behind high-dose amoxicillin therapy for otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies","volume":"41","author":"Lister","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/infdis\/162.2.414","article-title":"Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation","volume":"162","author":"Daikos","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2005.10.038_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/AAC.35.1.117","article-title":"First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use","volume":"35","author":"Daikos","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1099\/00222615-29-1-41","article-title":"Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa","volume":"29","author":"Gilleland","year":"1989","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.bcp.2005.10.038_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/43.1.79","article-title":"Pharmacodynamics of levofloxacin and ciprofloxacin against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae","volume":"43","author":"Lister","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/AAC.43.5.1118","article-title":"Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model","volume":"43","author":"Lister","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib20","series-title":"Antibiotics in laboratory medicine.","first-page":"296","article-title":"Postantibiotic-effect","author":"Craig","year":"1996"},{"key":"10.1016\/j.bcp.2005.10.038_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1128\/JB.56.1.75-81.1948","article-title":"The action of penicillin on staphylococcus: further observations on the effect of a short exposure","volume":"56","author":"Parker","year":"1948","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bcp.2005.10.038_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/JB.58.4.475-490.1949","article-title":"The slow recovery of bacterial from the toxic effects of penicillin","volume":"58","author":"Eagle","year":"1949","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bcp.2005.10.038_bib23","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1128\/AAC.35.9.1834","article-title":"Pharmacodynamic effects of subinhibitory concentrations of \u00df-lactam antibiotics in vitro","volume":"35","author":"Odenholt-Tornqvist","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl D","key":"10.1016\/j.bcp.2005.10.038_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jac\/31.suppl_D.159","article-title":"The post-antibiotic sub-MIC effect in vitro and in vivo","volume":"31","author":"Cars","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/clinids\/3.1.98","article-title":"Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits: preliminary observations on the postantibiotic effect in vivo","volume":"3","author":"Sande","year":"1981","journal-title":"Rev Infect Dis"},{"issue":"Suppl C","key":"10.1016\/j.bcp.2005.10.038_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/27.suppl_C.29","article-title":"Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections","volume":"27","author":"Craig","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl D","key":"10.1016\/j.bcp.2005.10.038_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/31.suppl_D.149","article-title":"Post-antibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infections in man","volume":"31","author":"Craig","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl A","key":"10.1016\/j.bcp.2005.10.038_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/20.suppl_A.71","article-title":"Therapy of streptococcal endocarditis: correlation of animal models and clinical studies","volume":"20","author":"Scheld","year":"1987","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl D","key":"10.1016\/j.bcp.2005.10.038_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/31.suppl_D.71","article-title":"Experimental endocarditis: a review of its relevance to human endocarditis","volume":"31","author":"Carbon","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib30","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1128\/AAC.46.6.1746-1754.2002","article-title":"Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequntial i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pnuemonia requiring initial parenteral treatment","volume":"46","author":"Finch","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2005.10.038_bib32","series-title":"Antimicrobial pharmacodynamics in theory and clinical practice","first-page":"155","article-title":"Pharmacodynamics of quinolones","author":"Owens","year":"2002"},{"key":"10.1016\/j.bcp.2005.10.038_bib33","series-title":"Antimicrobial pharmacodynamics in theory and clinical practice","first-page":"125","article-title":"Aminoglycoside pharmacodynamics","author":"Kim","year":"2002"},{"key":"10.1016\/j.bcp.2005.10.038_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0891-5520(03)00057-6","article-title":"Pharmacodynamics and dosing of aminoglycosides","volume":"17","author":"Turnidge","year":"2003","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2005.10.038_bib35","doi-asserted-by":"crossref","first-page":"2S27","DOI":"10.1111\/j.1469-0691.1998.tb00692.x","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"4","author":"Drusano","year":"1998","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bcp.2005.10.038_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.bcp.2005.10.038_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diag Microbiol Infect Dis"},{"key":"10.1016\/j.bcp.2005.10.038_bib38","series-title":"Antimicrobial pharmacodynamics in theory and clinical practice","first-page":"99","article-title":"Beta-lactam pharmacodynamics","author":"McNabb","year":"2002"},{"key":"10.1016\/j.bcp.2005.10.038_bib39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/147.5.910","article-title":"Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice","volume":"147","author":"Gerber","year":"1983","journal-title":"J Infect Dis"},{"issue":"6A","key":"10.1016\/j.bcp.2005.10.038_bib40","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1016\/0002-9343(91)90311-K","article-title":"Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones","volume":"91","author":"Dudley","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.bcp.2005.10.038_bib41","first-page":"299","article-title":"Awakening the slumbering potential of the 4-quinolone antibacterials","volume":"233","author":"Smith","year":"1984","journal-title":"Pharm J"},{"key":"10.1016\/j.bcp.2005.10.038_bib42","series-title":"Physicians\u2019 desk reference","author":"Thomson","year":"2004"},{"key":"10.1016\/j.bcp.2005.10.038_bib43","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750mg, 5-day levofloxcain in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr Med Resp Opin"},{"key":"10.1016\/j.bcp.2005.10.038_bib44","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2005.10.038_bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0891-5520(03)00061-8","article-title":"Clinical pharmacodynamics of quinolones","author":"Ambrose","year":"2003","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2005.10.038_bib46","first-page":"S227","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.bcp.2005.10.038_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1469-0691.2000.tb02040.x","article-title":"Pharmacokinetics of antibiotics with special emphasis on cephalosporins","volume":"6","author":"Craig","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bcp.2005.10.038_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1128\/AAC.46.1.69-74.2002","article-title":"Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae: impact of AUC:MIC ratios on eradication from an in vitro pharmacodynamic model","volume":"46","author":"Lister","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2005.10.038_bib49","series-title":"Antimicrobial pharmacodynamics in theory and clinical practice","first-page":"1","article-title":"Pharmacodynamics of antimicrobials: general concepts and applications","author":"Craig","year":"2002"},{"key":"10.1016\/j.bcp.2005.10.038_bib50","series-title":"Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Pharmacodynamic activity of a new oxazolidinone in an animal infection model","author":"Andes","year":"1998"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295205007124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295205007124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T06:54:08Z","timestamp":1586588048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295205007124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0006295205007124"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2005.10.038","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}